Spyre Therapeutics appoints Dr. Sandra Milligan to its Board of Directors and announces Board member Jeff Albers as new Chairman

– USA, MA –  Spyre Therapeutics, Inc. (NASDAQ: SYRE), a development-stage biotechnology company, today announced the appointment of Dr. Sandra Milligan (M.D., J.D.) to its Board of Directors.

“With a distinguished career spanning leadership roles at large and small biopharmaceutical companies, Dr. Milligan brings deep expertise in clinical development and regulatory affairs, including within IBD, that will be invaluable as we execute on our strategy to deliver novel therapies that improve both efficacy and convenience compared to today’s standard of care. We are excited to incorporate her guidance as we progress our novel antibody therapies targeting α4β7 and TL1A into clinical studies in the upcoming months,” said CEO Cameron Turtle.

The company also announced the appointment of current Board member Jeff Albers as Chairman of the Board of Directors effective May 13, 2024, succeeding Russell Cox who stepped down from the Board.

About Dr. Sandra Milligan

Dr. Sandra Milligan served as the Head of Research and Development of Organon & Co. Previously, she served in key executive positions, including SVP and Head of Global Regulatory Affairs and Clinical Safety at Merck; VP of Product Development Regulatory at Genentech, Inc.; and important roles across legal and regulatory affairs at Amgen Inc.

“As a physician, Spyre’s commitment to scientific excellence and patient-centric innovation resonates deeply with me,” said Dr. Sandra Milligan. “I am honored to join this accomplished team of leaders and eager to collaborate in their goal to drive meaningful advancements in IBD treatment toward improving lives.”

About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23.

SOURCE: www.spyre.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.